Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


April 17, 2013 - CML- Living with a Chronic Disease

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: April 17, 2013
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
View: Program Slides | Diapositivas (Spanish program slides)
Read: CML News Links (English and Spanish) | Transcript
Listen: Presentation | Q&A Session | Presentación y sesión de preguntas (Spanish audio) | Sesión de preguntas extendido (Spanish extended Q&A)
Access: Virtual Lecture

Topics Covered

  • Current treatment options for CML patients
  • CML therapies
  • Key elements of monitoring response to CML treatment
  • The role of clinical trials in the advancement of CML treatment
  • Quality of life issues for patients living with CML
  • Communication touch points among patients and healthcare providers 


Jorge Cortes, MD
D.B. Lane Cancer Research Distinguished Professor for Leukemia Research
Deputy Chairman, Section Chief of AML & CML
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Questions Asked by the CML Community

  • Should a patient discontinue taking dasatinb (Sprycel®) after eight years due to memory issues?
  • Have there been any studies on imatinib (Gleevec®) and its implication on cognitive development?
  • What is the percent of CML patients now that need to have a stem cell transplant?
  • Can you talk about fertility in male patients on Sprycel?
  • If Gleevec stopped working after three years, would the next treatment option be to start taking ponatinib (IclusigTM) and also try a stem cell program?
  • If a younger person needs to take nilotinib (Tasigna®) for many years, is there concern about organ problems happening in the future?
  • Can you participate in a clinical trial if your disease is undetectable? 
  • What kinds of options exist to monitor CML if the PCR tests are not available?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Novartis Oncology and Bristol-Myers Squibb.

last updated on Tuesday, November 18, 2014